| Samantha L Melady, AG-ACNP | |
|
1215 Lee St, Charlottesville, VA 22908-0816 | |
| (434) 243-1000 | |
| (434) 244-7551 |
| Full Name | Samantha L Melady |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Gerontology |
| Location | 1215 Lee St, Charlottesville, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205518586 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 0001263486 (Virginia) | Secondary |
| 363LG0600X | Nurse Practitioner - Gerontology | 0001263486 (Virginia) | Primary |
| Entity Name | University Of Virginia Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033138250 PECOS PAC ID: 4880590728 Enrollment ID: O20040102000780 |
News Archive
Javelin Pharmaceuticals, Inc., a leading developer of novel acute care pain products, today reported its unaudited financial results for the third quarter ended September 30, 2009.
A team of scientists, led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine, has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.
Alexandria Real Estate Equities, Inc., the largest and leading REIT uniquely focused on collaborative science campuses in urban innovation clusters, announced today that Bristol-Myers Squibb, a global biopharmaceutical company, will establish a state-of-the-art research and development center at the Alexandria Center at Kendall Square (ACKS) in the heart of the Cambridge Kendall Square innovation cluster.
Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Samantha L Melady, AG-ACNP Po Box 9007, Charlottesville, VA 22906-9007 Ph: () - | Samantha L Melady, AG-ACNP 1215 Lee St, Charlottesville, VA 22908-0816 Ph: (434) 243-1000 |
News Archive
Javelin Pharmaceuticals, Inc., a leading developer of novel acute care pain products, today reported its unaudited financial results for the third quarter ended September 30, 2009.
A team of scientists, led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine, has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.
Alexandria Real Estate Equities, Inc., the largest and leading REIT uniquely focused on collaborative science campuses in urban innovation clusters, announced today that Bristol-Myers Squibb, a global biopharmaceutical company, will establish a state-of-the-art research and development center at the Alexandria Center at Kendall Square (ACKS) in the heart of the Cambridge Kendall Square innovation cluster.
Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.
› Verified 7 days ago